The safety of sublingual-swallow immunotherapy: an analysis of published studies (Q36130311)

12 August 2017

1 reference

title

The safety of sublingual-swallow immunotherapy: an analysis of published studies (English)

1 reference

12 August 2017

1 reference

Gidaro GB

1

1 reference

12 August 2017

Marcucci F

2

1 reference

12 August 2017

Sensi L

3

1 reference

12 August 2017

Incorvaia C

4

1 reference

12 August 2017

Frati F

5

1 reference

12 August 2017

Ciprandi G

6

1 reference

12 August 2017

publication date

1 May 2005

1 reference

Clinical & Experimental Allergy

12 August 2017

published in

1 reference

12 August 2017

volume

35

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

565-571

1 reference

25. Immunotherapy of allergic disease

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

Noninjection routes for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

Sublingual immunotherapy: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

Safety of sublingual-swallow immunotherapy in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

Systemic reactions from allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2222.2005.02240.X

10.1111/J.1365-2222.2005.02240.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference